Demographic and clinical features of nine PD patients tested in the “off” state
| Subject | Gender | Age | Stagea | UPDRSb | Symptom duration (years)c | Medications |
|---|---|---|---|---|---|---|
| 1 | F | 78 | 2.5 | 18.5 | 3 | Levo, Am, Sel |
| 2 | M | 70 | 2.5 | 20.5 | 3 | Br, Sel |
| 3 | M | 62 | 2.0 | 25.0 | 4 | Levo-SR |
| 4 | M | 58 | 2.8 | 35.0 | 5 | Levo-SR, Sel |
| 5 | M | 80 | 2.5 | 24.0 | 6 | Levo-SR |
| 6 | M | 75 | 2.0 | 31.5 | 8 | Tri, Sel |
| 7 | M | 78 | 3.0 | 30.5 | 9 | None |
| 8 | M | 72 | 2.0 | 24.0 | 11 | Levo-SR, Per, Sel |
| 9 | M | 73 | 2 | 24.7 | 25 | Levo, Per, Tri |
UPDRS, Unified Parkinson's disease rating scale, motor subscale; Am, amantidine; Br, bromociptine; Levo, carbidopa/levodopa (regular formulation); Levo-SR, carbidopa/levodopa sustained release; Per, pergolide; Sel, selegiline; Tri, trihexyphenidyl; M, male; F, female.
↵aHoehn and Yahr stage (Hoehn and Yahr, 1967).
↵bThe maximum score is 108.
↵cRefers to number of years since first remembered parkinsonian symptoms.